Wire · opportunities
Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 9 September 2026 · Fusion42 review
Rezolute provided an update on the FDA's ongoing review of Phase 3 sunRIZE study data for ersodetug to treat congenital hyperinsulinism, highlighting improvements in glycemic control but no statistically significant primary endpoint achievement. The FDA has not set a timeline for feedback, and the open-label extension phase shows potential longer-term benefits.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You face uncertain FDA timelines that could extend your launch horizon but promising longer-term use data in congenital hyperinsulinism opens a route for sustained patient benefit. Prepare to engage proactively with regulators while strengthening clinical evidence for your drug's effectiveness.
◆ Coverage
1 source · 9 Sep 2026
◆ Related on Wire
◆ Topics